Ursula A. Matulonis, MD, on Future Focus With Mirvetuximab Soravtansine in Ovarian Cancer

Ursula A. Matulonis, MD, speaks to potential future uses of mirvetuximab soravtansine in ovarian cancer.

Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer about future directions with mirvetuximab soravtansine (IMGN853) in ovarian cancer.

In addition to hoping that the drug will become a standard for the folate receptor α (FRα)–high platinum-resistant population following treatment with bevacizumab (Avastin), she explains that it may also have a role in platinum-sensitive and newly diagnosed advanced disease.


We’re hoping this drug is going to have a standard of care place for patients with [FRα-high] platinum-resistant, high-grade serous ovarian cancer [who] received prior bevacizumab through an accelerated approval. Certainly, this drug is combinable with other agents, such as bevacizumab and [platinum-based chemotherapy]. Right now, this trial is in more heavily pretreated patients with platinum-resistant ovarian cancer, but I definitely can see a role for it in platinum-sensitive disease, and also even moving it up front for patients with newly diagnosed advanced ovarian cancer.


Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.

Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.